References
- Levin TN, Samaha F, Follman D, et al. Right ventricular MI: when to suspect, what to do. J Crit Illness 1995; 10(1):14–24
- McGhie AI, Golstein RA. Pathogenesis and management of acute heart failure and cardiogenic shock: role of inotropic therapy. Chest 1992; 102(5 Suppl 2):626–32S
- Hochman JS, Boland J, Sleeper LA, et al. Current spectrum of cardiogenic shock and effect of early revascularization on mortality: results of an international registry. Circulation 1995; 91(3):873–81
- Califf-RM, Bengtson JR. Cardiogenic shock. N Engl J Med 1994; 330(24):1724–30
- Moosvi AR, Khaja F, Villanueva L, et al. Early revascularization improves survival in cardiogenic shock complicating acute myocardial infarction. J Am Coll Cardiol 1992; 19(5):907–14
- Forrester JS, Diamond G, Chatterjee K, et al. Medical therapy of acute myocardial infarction by application of hemodynamic subsets I. N Engl J Med 1976; 295(24):1356–62
- Swan HJ, Ganz W, Forrester J, et al. Catheterization of the heart in man with use of a flow-directed balloon-tipped catheter. N Engl J Med 1970; 283(9):447–51
- Sharkey SW. Beyond the wedge: clinical physiology and the Swan-Ganz catheter. AmJ Med 1987; 83(1):111–22
- Shipley JB, Tolman DE, Hess ML. When—and how—to use inotropic therapy for congestive heart failure: will its short-term efficacy ever produce long-term benefit? J Crit Illness 1995; 10(2):94–102
- Houston MC, Thompson L, Robertson D. Shock: diagnosis and management. Arch Intern Med 1984; 144(Jul):1433–9
- Karlsberg RP, De Wood MA, DeMaria AN, et al. Comparative efficacy of short-term intravenous infusions of milrinone and dobutamine in acute congestive heart failure following acute myocardial infarction. Clin Cardiol 1996; 19:21–30
- Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991; 325(21):1468–75
- Colucci WS, Wright RF, Jaski BE, et al. Milrinone and dobu- tamine in severe heart failure: differing hemodynamic effects and individual patient responsiveness. Circulation 1986; 73(3 Pt 2): 175–83III
- Sorrentino M, Feldman T. Techniques for IABP timing, use—and discontinuance. J Crit Illness 1992; 7(4):597–604
- Garg R, Yusuf S. Overview of randomized trials of angiotensin- converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273(18):1450–6 [Erratum, JAMA 1995; 274(6):462]
- Feldman AM, Bristow MR, Parmley WW, et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med 1993; 329(3):149–55